A randomized pilot phase II trial of adjuvant immunization with G250 peptide [renal cancer vaccine] and three different dose levels of IL-2 [interleukin 2] following surgical resection of locally advanced or metastatic renal cell carcinoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interleukin-2; Renal cancer vaccine
- Indications Renal cancer
- Focus Therapeutic Use
- 05 Sep 2013 Biomarkers information updated
- 02 Jan 2008 Status changed from in progress to discontinued according to ClinicalTrials.gov.
- 29 Aug 2007 Status changed from recruiting to in progress.